Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype

Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780–2795

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947

Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871–3879

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X et al (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587–4594

Coiffier B (2005) Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 4:7–14

Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR et al (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14:943–951

Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M (1987) Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 316:79–84

Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88:386–401

Danial NN, Korsmeyer SJ (2005) Cell death: critical control points. Cell 116:205–219

Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876–885

Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al (2009) The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23:2034–2041

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389–399

Singh RR, Kim JE, Davuluri Y, Drakos E, Cho-Vega JH, Amin HM et al (2010) Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 24:1025–1036

Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA et al (2009) Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 22:1312–1320

Bigelow RL, Chari NS, Unden AB, Spurgers KB, Lee S, Roop DR et al (2004) Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 279:1197–1205

Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, Philpott MP et al (2004) Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 64:7724–7731

Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346–347

Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F et al (2011) ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30:4874–4886

van Meerloo J, Kaspers GJ, Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods Mol Biol 731:237–245

Su W, Meng F, Huang L, Zheng M, Liu W, Sun H (2012) Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through beta-catenin signaling. Exp Hematol 40:418–427

Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR et al (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944–951

Singh BN, Fu J, Srivastava RK, Shankar S (2011) Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 6:e27306

Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ (1987) Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80:1512–1515

Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S et al (2012) BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 26:1383–1390

Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C et al (2009) BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 106:11294–11299

O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S et al (1998) Bim: a novel member of the BCL-2 family that promotes apoptosis. EMBO J 17:384–395